Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Autor:
Jason H. Cheng, Douglas Den Otter, Hani Bou-Reslan, Vidusha Devasthali, Richard A.D. Carano, Emily Chan, Klaus P. Hoeflich, Anne C Clermont, Michelle Nannini, Mallika Singh, Ciara Metcalfe, Mark Merchant, Dorothy French, Joseph Castillo, Melissa R. Junttila, Tim C. Cao, William F. Forrest
Publikováno v:
Molecular Cancer Therapeutics. 14:40-47
Activating mutations in the KRAS oncogene occur in approximately 90% of pancreatic cancers, resulting in aberrant activation of the MAPK and the PI3K pathways, driving malignant progression. Significant efforts to develop targeted inhibitors of nodes
Autor:
Young Suk Park, Yoon-La Choi, Joon Oh Park, Hye Lim Jang, Seung Tae Kim, Do Hyoung Lim, Taekyu Lim, Kyung Kee Baek, Ho Yeong Lim, Won Ki Kang, Jeeyun Lee, Jun Ho Yi, Kee Taek Jang, Se Hoon Park
Publikováno v:
Molecular Cancer Therapeutics. 10:1993-1999
Although erlotinib has become an important therapeutic option in addition to gemcitabine, the high frequency of KRAS mutations in pancreatic cancer probably limits the benefits. We retrospectively studied 136 pancreatic cancer patients with available
Publikováno v:
Molecular Cancer Therapeutics. 17:LB-B29
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal cancer with mortality closely paralleling incidence despite substantial advances in biological understanding of the disease. Nab-paclitaxel (NPT) plus Gemcitabine (Gem) represents the cu
Autor:
Michele T. Yip-Schneider, Harikrishna Nakshatri, C. Max Schmidt, Eric A. Wiebke, Christopher Sweeney, Mark S. Marshall
Publikováno v:
Molecular Cancer Therapeutics. 4:587-594
Activation of the transcription factor nuclear factor-kappa B (NF-kappa B) has been implicated in pancreatic tumorigenesis. We evaluated the effect of a novel NF-kappa B inhibitor, parthenolide, a sesquiterpene lactone isolated from the herb feverfew
Autor:
Todd VanArsdale, Beatriz Salvador, James S. Hardwick, Camino Menéndez, Pedro P. López-Casas, Xianxian Zheng, Tao Xie, Paul A. Rejto, Peter Olson, David J. Shields, Jing Yuan, John Chionis, Manuel Hidalgo
Publikováno v:
Molecular Cancer Therapeutics. 14:A42-A42
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with a 5 year survival rate of less than 5%. Deaths caused by pancreatic cancer are projected to exceed the number from colorectal carcinoma by 2020, making PDAC the seco
Autor:
Venessa T. Chin, Ray Asghari, Val Gebski, Lorraine A. Chantrill, Andrew V. Biankin, Nicola Waddell, John Simes, Sonia Yip, Peter Grimison, John F. Pearson, Sandra Harvey, David Miller, Nick Pavlakis, Chee Lee, Amber L. Johns, Scott Mead, Angela Chou, Sean M. Grimmond, Mark Pinese, Lucille Sebastian, Adnan Nagrial, Sanjay Mukhedkar, Danielle Miller, Katrin Marie Sjoquist
Publikováno v:
Molecular Cancer Therapeutics. 12:A75-A75
Background: Less than 5% of patients with metastatic pancreatic cancer survive to 5 years and there have been no major improvements in outcomes over the last 20 years. The use of treatments targeted according to the molecular phenotype of individual
Autor:
Shuya Yano, Jason B. Fleming, Shinji Miwa, Ali Maawy, Robert M. Hoffman, Takashi Chishima, Atsushi Suetsugu, Yong Zhang, Masashi Momiyama, Fuminari Uehara, Yukihiko Hiroshima, Itaru Endo, Matthew H.G. Katz, Kuniya Tanaka, Michael Bouvet, Ming Zhao
Publikováno v:
Molecular Cancer Therapeutics. 12:B13-B13
The aim of this study is to determine the efficacy of tumor-targeting Salmonella typhimurium A1-R (A1-R) on pancreatic cancer patient-derived orthotopic xenografts (PDOX) in nude mice compared to standard chemotherapy. The pancreatic cancer PDOX was
Autor:
Mark Manfredi, Julie Zhang, Petter Veiby, Hadi Danaee, Tim Wyant, Melissa Gallery, Brad Stringer
Publikováno v:
Molecular Cancer Therapeutics. 12:PR12-PR12
Background: MLN0264 consists of a fully human anti-GCC monoclonal antibody linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker (MMAE and linker technology licensed from Seattle Genetics). The tran
Publikováno v:
Molecular Cancer Therapeutics. 12:A234-A234
Pancreatic cancer is one of the leading causes of cancer-related death in the United States and no effective therapeutic options are currently available. The lethality of pancreatic cancer, due to the aggressiveness of the disease and the lack of eff
Publikováno v:
Molecular Cancer Therapeutics. 12:B104-B104
Introduction: Pancreatic adenocarcinoma a highly lethal malignancy (5 yr survival ∼ 5%) is poorly responsive to all chemotherapy, in part related to presence of chemo resistant pathways: prosurvival (AKT/PI3K/mTOR and mutant KRAS. We have previousl